

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ^b: C07D 207/06, 211/14, A61K 31/40, 31/445	A1	(11) International Publication Number: WO 98/13343 (43) International Publication Date: 2 April 1998 (02.04.98)
(21) International Application Number: PCT/US97/15832 (22) International Filing Date: 9 September 1997 (09.09.97) (30) Priority Data: 08/721,765 25 September 1996 (25.09.96) US 08/904,461 1 August 1997 (01.08.97) US (71) Applicant: GUILFORD PHARMACEUTICALS INC. [US/US]; 6611 Tributary Street, Baltimore, MD 21224 (US). (72) Inventors: HAMILTON, Gregory, S.; 6501 Frederick Road, Cantonsville, MD 21228 (US). LI, Jia-He; 27 Warren Manor Court, Cockeysville, MD 21030 (US). (74) Agent: NATH, Gary, M.; Nath & Associates, Suite 750, 1835 K Street, N.W., Washington, DC 20006-1203 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: HETEROCYCLIC THIOESTERS AND KETONES		
(57) Abstract		
<p>This invention relates to neurotrophic low molecular weight, small molecule heterocyclic thioesters and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.</p>		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

HETEROCYCLIC THIOESTERS AND KETONES

This application is a continuation-in-part of U.S. Patent Application No. 08/721,765, filed September 25, 1996, the entire content of which is herein incorporated by reference.

BACKGROUND OF THE INVENTION

1. Field of Invention

This invention relates to neurotrophic low molecular weight, small molecule heterocyclic thioesters and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

2. Description of Related Art

The term immunophilin refers to a number of proteins that serve as receptors for the principal immunosuppressant drugs, cyclosporin A (CsA), FK506 and rapamycin. Known classes of immunophilins are cyclophilins and FK506 binding proteins, or FKBP. Cyclosporin A binds to cyclophilin A while FK506 and rapamycin bind to FKBP12. These immunophilin-drug complexes interface with various intracellular signal transduction systems, especially the immune and nervous systems.

Immunophilins are known to have peptidyl-prolyl isomerase (PPIase), or rotamase, enzyme activity. It has been determined that rotamase enzyme activity plays a role in the catalyzation of the interconversion of the cis and trans isomers of peptide and protein substrates for the immunophilin proteins.

Immunophilins were originally discovered and studied in the immune tissue. It was initially postulated by those skilled in the art that inhibition of the immunophilins' rotamase activity leads to inhibition of T-cell proliferation, thereby causing the immunosuppressive activity exhibited by immunosuppressant drugs, such as cyclosporin A, FK506 and rapamycin. Further study has shown that the inhibition of rotamase activity, in and of itself, does not result in immunosuppressive activity. Schreiber et al., *Science*, 1990, vol. 250, pp. 556-559. Instead, immunosuppression appears to stem from the formulation of a complex of immunosuppressant drug and immunophilin. It has been shown that the immunophilin-drug complexes interact with ternary protein targets as their mode of action. Schreiber et al., *Cell*, 1991, vol. 66, pp. 807-815. In the case of FKBP-FK506 and cyclophilin-CsA, the immunophilin-drug complexes bind to the enzyme calcineurin and inhibit the T-cell receptor signalling which leads to T-cell proliferation. Similarly, the

immunophilin-drug complex of FKBP-rapamycin interacts with the RAFT1/FRAP protein and inhibits the IL-2 receptor signalling.

Immunophilins have been found to be present at high concentrations in the central nervous system. Immunophilins are enriched 10-50 times more in the central nervous system than in the immune system. Within neural tissues, immunophilins appear to influence nitric oxide synthesis, neurotransmitter release and neuronal process extension.

It has been found that picomolar concentrations of an immunosuppressant such as FK506 and rapamycin stimulate neurite outgrowth in PC12 cells and sensory neurons, namely dorsal root ganglion cells (DRGs). Lyons et al., Proc. of Natl. Acad. Sci., 1994, vol. 91, pp. 3191-3195. In whole animal experiments, FK506 has been shown to stimulate nerve regeneration following facial nerve injury.

Surprisingly, it has been found that certain compounds with a high affinity for FKBP are potent rotamase inhibitors and exhibit excellent neurotrophic effects. Furthermore, these rotamase inhibitors are devoid of immunosuppressive activity. These findings suggest the use of rotamase inhibitors in treating various peripheral neuropathies and enhancing neuronal regrowth in the central nervous system (CNS). Studies

have demonstrated that neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), may occur due to the loss, or decreased availability, of a neurotrophic substance specific for a particular population of neurons affected in the disorder.

Several neurotrophic factors affecting specific neuronal populations in the central nervous system have been identified. For example, it has been hypothesized that Alzheimer's disease results from a decrease or loss of nerve growth factor (NGF). It has thus been proposed to treat SDAT patients with exogenous nerve growth factor or other neurotrophic proteins, such as brain derived growth factor, glial derived growth factor, ciliary neurotrophic factor and neurotrophin-3, to increase the survival of degenerating neuronal populations.

Clinical application of these proteins in various neurological disease states is hampered by difficulties in the delivery and bioavailability of large proteins to nervous system targets. By contrast, immunosuppressant drugs with neurotrophic activity are relatively small and display excellent bioavailability and specificity. However, when administered chronically, immunosuppressant drugs exhibit a number of potentially serious side effects including nephrotoxicity, such as impairment of glomerular filtration and irreversible interstitial

fibrosis (Kopp et al., *J. Am. Soc. Nephrol.*, 1991, 1:162); neurological deficits, such as involuntary tremors, or non-specific cerebral angina, such as non-localized headaches (De Groen et al., *N. Engl. J. Med.*, 1987, 317:861); and vascular hypertension with complications resulting therefrom (Kahan et al., *N. Engl. J. Med.*, 1989, 321:1725).

To prevent the side effects associated with use of the immunosuppressant compounds, the present invention provides non-immunosuppressive compounds containing small molecule FKBP rotamase inhibitors for enhancing neurite outgrowth, and promoting neuronal growth and regeneration in various neuropathological situations where neuronal repair can be facilitated, including: peripheral nerve damage caused by physical injury or disease state such as diabetes; physical damage to the central nervous system (spinal cord and brain); brain damage associated with stroke; and neurological disorders relating to neurodegeneration, such as Parkinson's disease, SDAT (Alzheimer's disease) and amyotrophic lateral sclerosis.


SUMMARY OF THE INVENTION

The present invention relates to neurotrophic low molecular weight, small molecule compounds having an affinity for FKBP-type immunophilins. Once bound to these proteins, the neurotrophic compounds are potent

inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity. A key feature of the compounds of the present invention is that they do not exert any significant immunosuppressive activity in addition to their neurotrophic activity.

Specifically, the present invention relates to a compound of formula II:

10



II

15

or a pharmaceutically acceptable salt thereof, wherein:

n is 1 or 2;

X is O or S;

Z is selected from the group consisting of S, CH₂,

20

CHR₁ and C(R₁)₂;

R₁ is selected from the group consisting of C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, Ar₁ and mixtures thereof, wherein said R₁ is unsubstituted or substituted with halo, nitro, C₁-C₆ straight or branched chain alkyl, C₁-C₆ straight or branched chain alkenyl, hydroxy, C₁-C₄ alkoxy, C₂-C₄

25

alkenyloxy, phenoxy, benzyloxy, amino, Ar₁ or a mixture thereof;

R₂ is selected from the group consisting of C₁-C₆, straight or branched chain alkyl, C₂-C₆, straight or branched chain alkenyl, C₃-C₆, cycloalkyl, C₅-C₆, cycloalkenyl and Ar₂; and

Ar₁ is phenyl, benzyl, pyridyl, fluorenyl, thioindolyl or naphthyl wherein said Ar₁ is unsubstituted or substituted with halo, hydroxy, nitro, C₁-C₆, straight or branched chain alkyl, C₂-C₆, straight or branched chain alkenyl, C₁-C₆, alkoxy, C₂-C₆, alkenyloxy, phenoxy, benzyloxy, amino or a mixture thereof.

The present invention also relates to a pharmaceutical composition comprising:

- (i) an effective amount of the compound of claim 1 for effecting a neuronal activity; and
(ii) a pharmaceutically acceptable carrier.

The present invention further relates to a method of effecting a neuronal activity in an animal, comprising:

administering to the animal an effective amount of the compound of formula II.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1(A) is a representative photomicrograph of untreated sensory neurons.

FIG. 1(B) is a representative photomicrograph of compound 1 (10 pM) promoting neurite outgrowth in sensory neurons.

5 FIG. 1(C) is a representative photomicrograph of compound 1 (1 nM) promoting neurite outgrowth in sensory neurons.

FIG. 1(D) is a representative photomicrograph of compound 1 (1 μ M) promoting neurite outgrowth in sensory neurons.

10 FIG. 2(A) is a representative photomicrograph of untreated sensory neurons.

FIG. 2(B) is a representative photomicrograph of compound 9 (10 pM) promoting neurite outgrowth in sensory neurons.

15 FIG. 2(C) is a representative photomicrograph of compound 9 (1 nM) promoting neurite outgrowth in sensory neurons.

20 FIG. 2(D) is a representative photomicrograph of compound 9 (100 nM) promoting neurite outgrowth in sensory neurons.

FIG. 3(A) is a representative photomicrograph of untreated sensory neurons.

25 FIG. 3(B) is a representative photomicrograph of compound 10 (10 pM) promoting neurite outgrowth in sensory neurons.

FIG. 3(C) is a representative photomicrograph of compound 9 (1 nM) promoting neurite outgrowth in sensory neurons.

FIG. 3(D) is a representative photomicrograph of compound 9 (100 nM) promoting neurite outgrowth in sensory neurons.

FIG. 4 presents quantitation for the recovery of TH-positive dopaminergic neurons in the striatum of animals receiving compounds 1, 9 and 10.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

"Alkyl" refers to a branched or unbranched saturated hydrocarbon chain containing 1 to 6 carbon atoms, such as methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, n-pentyl, n-hexyl and the like, unless otherwise indicated.

"Alkoxy" refers to the group -OR wherein R is alkyl as herein defined. Preferably, R is a branched or unbranched saturated hydrocarbon chain containing 1 to 3 carbon atoms.

"Halo" refers to fluoro, chloro, bromo or iodo, unless otherwise indicated.

"Isomers" are different compounds that have the same molecular formula. "Stereoisomers" are isomers that differ only in the way the atoms are arranged in space.

"Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. "Diastereoisomers" are stereoisomers which are not mirror images of each other. "Racemic mixture" means a mixture
5 containing equal parts of individual enantiomers. "Non-racemic mixture" is a mixture containing unequal parts of individual enantiomers or stereoisomers.

"Pharmaceutically acceptable salt" refers to a salt of the inventive compounds which possesses the desired
10 pharmacological activity and which is neither biologically nor otherwise undesirable. The salt can be formed with inorganic acids such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate,
15 camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate,
20 methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, thiocyanate, tosylate and undecanoate. Examples of a base salt include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with
25 organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine

and lysine. Also, the basic nitrogen-containing groups can be quarternized with agents including: lower alkyl halides such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides; dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aralkyl halides such as benzyl and phenethyl bromides.

"Phenyl" refers to any possible isomeric phenyl radical, optionally monosubstituted or multisubstituted with substituents selected from the group consisting of alkyl, alkoxy, hydroxy, halo and haloalkyl.

"Treating" refers to:

(i) preventing a disease, disorder or condition from occurring in an animal which may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it;

(ii) inhibiting the disease, disorder or condition, i.e., arresting its development; and

(iii) relieving the disease, disorder or condition, i.e., causing regression of the disease, disorder and/or condition.

Compounds of the Invention


The neurotrophic low molecular weight, small molecule FKBP inhibitor compounds of this invention have

12

an affinity for FKBP-type immunophilins, such as FKBP12. When the neurotrophic compounds of this invention are bound to an FKBP-type immunophilin, they have been found to inhibit the prolyl-peptidyl cis-trans isomerase activity, or rotamase, activity of the binding protein and unexpectedly stimulate neurite growth.

FORMULA I

In particular, this invention relates to a compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:

A and B, together with the nitrogen and carbon atoms to which they are respectfully attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing any combination of CH₂, O, S, SO, SO₂, NH or NR₂ in any chemically stable oxidation state;

X is either O or S;

Z is either S, CH₂, CHR₁ or C(R₁)₂;

W and Y are independently O, S, CH₂ or H₂;

R₁ is C₁-C₆ straight or branched chain alkyl or alkenyl, which is substituted in one or more position(s) with (Ar₁)_n, (Ar₂)_n connected by a C₁-C₆ straight or branched chain alkyl or alkenyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl connected by a C₁-C₆ straight or branched chain alkyl or alkenyl, Ar₁ or a combination thereof;

n is 1 or 2;

R₂ is either C₁-C₆ straight or branched chain alkyl or alkenyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkenyl or Ar₁, wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl is either unsubstituted or substituted in one or more position(s) with C₁-C₆ straight or branched chain alkyl or alkenyl, hydroxyl or a combination thereof; and

Ar₁ and Ar₂ are independently a mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted in one to three position(s) with halo, hydroxyl, nitro, trifluoromethyl, C₁-C₆ straight or branched chain alkyl or alkenyl, C₁-C₆ alkoxy, C₁-C₆ alkenyloxy, phenoxy, benzyloxy, amino or a combination thereof; wherein the individual ring sizes are 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) selected from the group consisting of O, N, S and a combination thereof.

14


Suitable mono- and bicyclic, carbo- and heterocyclic rings include, without limitation, naphthyl, indolyl, furyl, thiazolyl, thienyl, pyridyl, quinoliny, isoquinoliny, fluorenyl and phenyl.

5

FORMULA II

A preferred embodiment of this invention is a compound of formula II:

10



II

15

or a pharmaceutically acceptable salt thereof, wherein:

n is 1 or 2;

X is O or S;

Z is selected from the group consisting of S, CH₂,

20

CHR₁ and C(R₁)₂;

R₁ is selected from the group consisting of C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, Ar₁ and mixtures thereof, wherein said R₁ is unsubstituted or substituted with halo, nitro, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, hydroxy, C₁-C₄ alkoxy, C₂-C₆

25

alkenyloxy, phenoxy, benzyloxy, amino, Ar₁ or a mixture thereof;

R₁ is selected from the group consisting of C₁-C₈ straight or branched chain alkyl, C₂-C₈ straight or branched chain alkenyl, C₁-C₈ cycloalkyl, C₃-C₈ cycloalkenyl and Ar₁; and

Ar₁ is phenyl, benzyl, pyridyl, fluorenyl, thioindolyl or naphthyl wherein said Ar₁ is unsubstituted or substituted with halo, hydroxy, nitro, C₁-C₈ straight or branched chain alkyl, C₂-C₈ straight or branched chain alkenyl, C₁-C₈ alkoxy, C₂-C₈ alkenyloxy, phenoxy, benzyloxy, amino or a mixture thereof.

Specific examples of these embodiments are presented in TABLE I.

15

TABLE I

No.	n	X	Z	R ₁	R ₂
20	1	O	CH ₂	3-Phenylpropyl	3,3-Dimethylpentyl
	2	O	CH ₂	3-(3-Pyridyl)propyl	3,3-Dimethylpentyl
	3	O	CH ₂	3-Phenylpropyl	tert-Butyl
	4	O	CH ₂	3-(3-Pyridyl)propyl	tert-Butyl
	5	O	CH ₂	3-(3-Pyridyl)propyl	Cyclohexyl
25	6	O	CH ₂	3-(3-Pyridyl)propyl	Cyclopentyl
	7	O	CH ₂	3-(3-Pyridyl)propyl	Cycloheptyl
	8	O	CH ₂	2-(9-Fluorenyl)ethyl	3,3-Dimethylpentyl
	9	O	S	2-Phenethyl	3,3-Dimethylpentyl
	10	O	S	2-Phenethyl	3,3-Dimethylpentyl

16

	11	1	O	S	Methyl(2-thioindole)	3,3-Dimethylpentyl
	12	1	O	S	2-Phenethyl	Cyclohexyl
	13	2	O	S	2-Phenethyl	tert-Butyl
	14	2	O	S	2-Phenethyl	Phenyl
5	15	1	O	CH ₂	3-(4-Methoxyphenyl)propyl	3,3-Dimethylpentyl
	16	2	O	CH ₂	4-(4-Methoxyphenyl)butyl	3,3-Dimethylpentyl
	17	2	O	CH ₂	4-Phenylbutyl	3,3-Dimethylpentyl
	18	2	O	CH ₂	4-Phenylbutyl	Phenyl
	19	2	O	CH ₂	4-Phenylbutyl	Cyclohexyl
10	20	1	S	CH ₂	3-Phenylpropyl	3,3-Dimethylpentyl
	21	1	S	S	2-Phenethyl	3,3-Dimethylpentyl
	22	2	S	CH ₂	3-Phenylpropyl	3,3-Dimethylpentyl
	23	2	S	S	2-Phenethyl	3,3-Dimethylpentyl
	24	2	O	CHR ₁	3-Phenylpropyl	3,3-Dimethylpentyl
15	25	2	O	CHR ₁	3-Phenylpropyl	Cyclohexyl
	26	2	O	CHR ₁	3-Phenylpropyl	Phenyl
	27	2	O	CHR ₁	3-Phenylpropyl	3,4,5-Trimethoxyphenyl
	28	1	O	S	2-Phenethyl	Cyclopentyl
	29	2	O	S	3-Phenylpropyl	tert-Butyl
20	30	1	O	S	3-Phenylpropyl	3,3-Dimethylpentyl
	31	1	O	S	3-(3-Pyridyl)propyl	3,3-Dimethylpentyl
	32	1	O	S	3-Phenylpropyl	Cyclohexyl
	33	1	O	S	4-Phenylbutyl	Cyclohexyl
	34	1	O	S	4-Phenylbutyl	3,3-Dimethylpentyl
25	35	1	O	S	3-(3-Pyridyl)propyl	Cyclohexyl
	36	1	O	S	3,3-Diphenylpropyl	3,3-Dimethylpentyl
	37	1	O	S	3,3-Diphenylpropyl	Cyclohexyl
	38	1	O	S	3-(4-Methoxyphenyl) propyl	3,3-Dimethylpentyl
30	39	2	O	S	4-Phenylbutyl	tert-Butyl

17

	40	2	O	S	1,5-Diphenylpentyl	3,3-Dimethylpentyl
	41	2	O	S	1,5-Diphenylpentyl	Phenyl
	42	2	O	S	3-(4-Methoxyphenyl)- propyl	3,3-Dimethylpentyl
5	43	2	O	S	3-(4-Methoxyphenyl)- propyl	Phenyl
	44	2	O	S	3-(1-Naphthyl)propyl	3,3-Dimethylpentyl
	45	1	O	S	3,3-Di(4-fluoro)phenyl- propyl	3,3-Dimethylpentyl
10	46	1	O	S	4,4-Di(4-fluoro)phenyl- butyl	3,3-Dimethylpentyl
	47	1	O	S	3-(1-Naphthyl)propyl	3,3-Dimethylpentyl
	48	1	O	S	2,2-Diphenylethyl	3,3-Dimethylpentyl
	49	2	O	S	2,2-Diphenylethyl	3,3-Dimethylpentyl
15	50	2	O	S	3,3-Diphenylpropyl	3,3-Dimethylpentyl
	51	1	O	S	3-(4-{Trifluoromethyl}- phenyl)propyl	3,3-Dimethylpentyl
	52	1	O	S	3-(2-Naphthyl)propyl	3,3-Dimethylpentyl
	53	2	O	S	3-(1-Naphthyl)propyl	3,3-Dimethylpentyl
20	54	1	O	S	3-(3-Chloro)phenylpropyl	3,3-Dimethylpentyl
	55	1	O	S	3-(3-{Trifluoromethyl}- phenyl)propyl	3,3-Dimethylpentyl
	56	1	O	S	3-(2-Biphenyl)propyl	3,3-Dimethylpentyl
	57	1	O	S	3,3-Dimethylpentyl	
25	58	1	O	S	3-(3-Fluorophenyl)propyl	3,3-Dimethylpentyl
	59	2	O	S	4-Phenylbutyl	3,3-Dimethylpentyl
	60	2	O	S	3-Phenylpropyl	3,3-Dimethylpentyl
	61	1	O	S	3-(2-Chloro)phenylpropyl	3,3-Dimethylpentyl
	62	2	O	S	3-(3-Chloro)phenylpropyl	3,3-Dimethylpentyl
30	63	2	O	S	3-(2-Fluoro)phenylpropyl	3,3-Dimethylpentyl

18

	64	2	O	S	3-(3-Fluoro)phenylpropyl	3,3-Dimethylpentyl
	65	1	O	S	3-(2,5-Dimethoxyphenyl)- propyl	3,3-Dimethylpentyl
	66	1	O	CH ₂	3-Phenylpropyl	Cyclohexyl
5	67	1	O	CH ₂	3-Phenylethyl	tert-Buryl
	68	2	O	CH ₂	4-Phenylburyl	Cyclohexyl
	69	2	O	CHR ₂	2-Phenylethyl	tert-Buryl
	70	1	O	CH ₂	3,3-Di(4-fluorophenyl)- propyl	3,3-Dimethylpentyl
10	71	2	O	CH ₂	3-Phenylpropyl	3,3-Dimethylpentyl

The most preferred examples of TABLE I are named as follows:

- 15 1 (2S)-2-({1-Oxo-5-phenyl}-pentyl-1-(3,3-dimethyl-1,2-dioxopentyl)pyrrolidine
- 2 3,3-Dimethyl-1-[(2S)-2-(5-(3-pyridyl)pentanoyl)-1-pyrrolidine]-1,2-pentanedione
- 3 (2S)-2-({1-Oxo-4-phenyl}-butyl-1-(3,3-dimethyl-1,2-dioxobutyl)pyrrolidine
- 20 9 2-Phenyl-1-ethyl 1-(3,3-dimethyl-1,2-dioxopentyl)-2-piperidinecarbothioate
- 10 2-Phenyl-1-ethyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate
- 25 11 (3-Thioindolyl)methyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate
- 12 2-Phenyl-1-ethyl (2S)-1-(2-cyclohexyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate

- 14 2-Phenyl-1-ethyl 1-(2-phenyl-1,2-dioxoethyl)-2-piperidinecarbothioate
- 28 2-Phenyl-1-ethyl (2S)-1-(1-cyclopentyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate
- 5 29 3-Phenyl-1-propyl 1-(3,3-dimethyl-1,2-dioxobutyl)-2-piperidinecarbothioate
- 30 3-Phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate
- 31 3-(3-Pyridyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate
- 10 32 3-Phenyl-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-pyrrolidinecarbothioate
- 33 4-Phenyl-1-butyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-pyrrolidinecarbothioate
- 15 34 4-Phenyl-1-butyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate
- 35 3-(3-Pyridyl)-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate
- 36 3,3-Diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate
- 20 37 3,3-Diphenyl-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate
- 38 3-(para-Methoxyphenyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate
- 25 39 4-Phenyl-1-butyl 1-(1,2-dioxo-3,3-dimethylbutyl)-2-piperidinecarbothioate


- 40 1,5-Diphenyl-3-pentyl 1-(3,3-dimethyl-1,2-dioxopentyl)-2-piperidinecarbothioate
- 41 1,5-Diphenyl-3-mercaptopentyl 1-(3-phenyl-1,2-dioxoethyl)-2-piperidinecarbothioate
- 5 42 3-(para-Methoxyphenyl)-1-propyl 1-(1,2-dioxo-3,3-dimethylpentyl)piperidine-2-carbothioate
- 43 3-(para-Methoxyphenyl)-1-propyl 1-(2-phenyl-1,2-dioxoethyl)piperidine-2-carbothioate
- 44 3-(1-Naphthyl)-1-propyl 1-(3,3-dimethyl-1,2-dioxopentyl)piperidine-2-carbothioate
- 10 45 3,3-Di(para-fluoro)phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate
- 46 4,4-Di(para-fluorophenyl)butyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate
- 15 47 3-(1-Naphthyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate
- 48 2,2-Diphenylethyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)tetrahydro-1H-2-pyrrolicarbothioate
- 49 2,2-Diphenylethyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate
- 20 50 3,3-Diphenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate
- 51 3-[4-(Trifluoromethyl)phenyl]propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate
- 25 52 3-(2-Naphthyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate

- 53 3-(2-Naphthyl)propyl (2R,S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate
- 54 3-(3-Chlorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate
- 5 55 3-[3-(Trifluoromethyl)phenyl]propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate
- 56 3-(1-Biphenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate
- 57 3-(2-Fluorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate
- 10 58 3-(3-Fluorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate
- 59 4-Phenylbutyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate
- 15 60 3-Phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate
- 61 3-(2-Chlorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate
- 62 3-(2-Chlorophenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate
- 20 63 3-(2-Fluorophenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate
- 64 3-(3-Fluorophenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate
- 25 65 3-(3,4-Dimethoxyphenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate

- 66 (2S)-2-({1-Oxo-4-phenyl}-butyl-1-(2-Cyclohexyl-1,2-dioxoethyl)pyrrolidine
- 67 2-({1-Oxo-4-phenyl}-butyl-1-(3,3-dimethyl-1,2-dioxobutyl)pyrrolidine
- 5 68 2-({1-Oxo-6-phenyl}-hexyl-1-(3,3-dimethyl-1,2-dioxobutyl)piperidine
- 69 2-({1-Oxo-[2-(2'-phenyl)ethyl]-4-phenyl}-butyl-1-(3,3-dimethyl-1,2-dioxobutyl)piperidine
- 70 1-((2S)-2-[5,5-di(4-Fluorophenyl)pentanoyl]-2-pyrrolidine)-3,3-dimethyl-1,2-pentanedione
- 10 71 3,3-Dimethyl-1-[2-(4-phenylpentanoyl)piperidino]-1,2-pentanedione

FORMULA III

15 Another preferred embodiment is a compound of formula III:



25 or a pharmaceutically acceptable salt thereof, wherein:

A, B, C and D are independently CH_2 , O, S, SO, SO_2 , NH or NR_2 ;

X is O or S;

Z is S, CH_2 , CHR_1 or $\text{C}(\text{R}_1)_2$;

5 R_1 is C_1 - C_6 straight or branched chain alkyl or alkenyl, which is substituted in one or more position(s) with $(\text{Ar}_1)_n$, $(\text{Ar}_1)_n$ connected by a C_1 - C_6 straight or branched chain alkyl or alkenyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl connected by a C_1 - C_6 straight or branched
10 chain alkyl or alkenyl, Ar_2 or a combination thereof;

n is 1 or 2;

R_2 is either C_1 - C_6 straight or branched chain alkyl or alkenyl, C_3 - C_6 cycloalkyl, C_5 - C_6 cycloalkenyl or Ar_1 , wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl
15 is either unsubstituted or substituted in one or more position(s) with C_1 - C_6 straight or branched chain alkyl or alkenyl, hydroxyl or a combination thereof; and

Ar_1 and Ar_2 are independently a mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring
20 is either unsubstituted or substituted in one to three position(s) with halo, hydroxyl, nitro, trifluoromethyl, C_1 - C_6 straight or branched chain alkyl or alkenyl, C_1 - C_6 alkoxy, C_1 - C_6 alkenyloxy, phenoxy, benzyloxy, amino or a combination thereof; wherein the individual ring sizes
25 are 5-6 members; and wherein the heterocyclic ring contains 1-5 heteroatom(s) selected from the group

consisting of O, N, S and a combination thereof.

Particularly preferred compounds of formula III are presented in TABLE II.

5

TABLE II

No.	A	B	C	X	Z	R ₁	R ₂
72	CH ₂	S	CH ₂	O	S	2-phenethyl	3,3-dimethyl-pentyl
73	CH ₂	S	CH ₂	O	CH ₂	3-phenylpropyl	3,3-dimethyl-pentyl
74	CH ₂	CH ₂	NH	C	S	2-phenethyl	3,3-dimethyl-pentyl
75	CH ₂	S	CH ₂	S	S	2-phenethyl	3,3-dimethyl-pentyl


10

15

FORMULA IV

A further preferred embodiment of this invention is a compound of formula IV:

25



IV

or a pharmaceutically acceptable salt thereof, wherein:

A, B, C and D are independently CH_2 , O, S, SO, SO_2 , NH or NR_2 ;

X is O or S;

5 Z is S, CH_2 , CHR_1 or $\text{C}(\text{R}_1)_2$;

R_1 is C_1 - C_6 straight or branched chain alkyl or alkenyl, which is substituted in one or more position(s) with $(\text{Ar}_1)_n$, $(\text{Ar}_1)_n$ connected by a C_1 - C_6 straight or branched chain alkyl or alkenyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl connected by a C_1 - C_6 straight or branched chain alkyl or alkenyl, Ar_2 or a combination thereof;

n is 1 or 2;

R_2 is either C_1 - C_6 straight or branched chain alkyl or alkenyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkenyl or Ar_1 , wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl is either unsubstituted or substituted in one or more position(s) with C_1 - C_6 straight or branched chain alkyl or alkenyl, hydroxyl or a combination thereof; and

Ar_1 and Ar_2 are independently a mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted in one to three position(s) with halo, hydroxyl, nitro, trifluoromethyl, C_1 - C_6 straight or branched chain alkyl or alkenyl, C_1 - C_6 alkoxy, C_1 - C_6 alkenyloxy, phenoxy, benzyloxy, amino or a combination thereof; wherein the individual ring sizes are 5-6 members; and wherein the heterocyclic ring

contains 1-6 heteroatom(s) selected from the group consisting of O, N, S and a combination thereof.

Particularly preferred compounds of formula IV are presented in TABLE III.

TABLE III

No.	A	B	C	D	X	Z	R ₁	R ₂
76	CH ₂	CH ₂	O	CH ₂	O	CH ₂	3-phenylpropyl	3,3-dimethylpentyl
77	CH ₂	CH ₂	O	CH ₂	O	S	2-phenethyl	3,3-dimethylpentyl
78	CH ₂	CH ₂	S	CH ₂	O	CH ₂	3-phenylpropyl	3,3-dimethylpentyl
79	CH ₂	CH ₂	S	CH ₂	O	S	2-phenethyl	3,3-dimethylpentyl

The compounds of this invention possess asymmetric centers and thus can be produced as mixtures of stereoisomers or as individual stereoisomers. The individual stereoisomers may be obtained by using an optically active starting material, by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis, or by resolving the compound of formula (I). It is understood that the individual stereoisomers as well as mixtures (racemic and non-racemic) of stereoisomers are encompassed by the scope of the present invention. The compounds of this invention possess at least one asymmetric center and thus can be produced as mixtures of stereoisomers or as

individual R- and S-stereoisomers. The individual enantiomers may be obtained by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis. It is understood that the individual R- and S- stereoisomers as well as mixtures of stereoisomers are encompassed by this invention. The S-stereoisomer is most preferred due to its greater activity.

10 Methods of Using the Compounds of the Invention

The compounds of the present invention have an affinity for the FK506 binding protein, particularly FKBP12, which is present in the brain. When the inventive compounds bind to FKBP in the brain, they exhibit excellent neurotrophic activity. This activity is useful in the stimulation of damaged neurons, the promotion of neuronal regeneration, the prevention of neurodegeneration, and the treatment of several neurological disorders known to be associated with neuronal degeneration and peripheral neuropathies.

For the foregoing reasons, the present invention further relates to a method of effecting a neuronal activity in an animal, comprising:

administering to the animal a neurotrophically effective amount of a compound of formula I, II, III or IV.

In a preferred embodiment, the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration and treatment of neurological disorder.

The neurological disorders that may be treated include but are not limited to: trigeminal neuralgia; glossopharyngeal neuralgia; Bell's Palsy; myasthenia gravis; muscular dystrophy; amyotrophic lateral sclerosis; progressive muscular atrophy; progressive bulbar inherited muscular atrophy; herniated, ruptured or prolapsed invertebrate disk syndromes; cervical spondylosis; plexus disorders; thoracic outlet destruction syndromes; peripheral neuropathies such as those caused by lead, dapsone, ticks, porphyria or Guillain-Barré syndrome; Alzheimer's disease; and Parkinson's disease.

The compounds of the present invention are particularly useful for treating a neurological disorder selected from the group consisting of: peripheral neuropathy caused by physical injury or disease state, traumatic injury to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorder relating to neurodegeneration. Examples of neurological disorders relating to neurodegeneration are Alzheimer's Disease, Parkinson's

Disease and amyotrophic lateral sclerosis.

For these purposes, the compounds may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an
5 implanted reservoir in dosage formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraperitoneally, intrathecally,
10 intraventricularly, intrasternal and intracranial injection or infusion techniques.

To be effective therapeutically as central nervous system targets, the compounds should readily penetrate the blood-brain barrier when peripherally administered.
15 Compounds which cannot penetrate the blood-brain barrier can be effectively administered by an intraventricular route.

The compounds may be administered in the form of sterile injectable preparations, for example, as sterile
20 injectable aqueous or oleaginous suspensions. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparations may also be sterile injectable solutions or
25 suspensions in non-toxic parenterally-acceptable diluents or solvents, for example, as solutions in 1,3-butanediol.

Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as solvents or suspending
5 mediums. For this purpose, any bland fixed oil such as a synthetic mono- or di-glyceride may be employed. Fatty acids such as oleic acid and its glyceride derivatives, including olive oil and castor oil, especially in their polyoxyethylated versions, are useful in the preparation
10 of injectables. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants.

Additionally, the compounds may be administered orally in the form of capsules, tablets, aqueous suspensions or solutions. Tablets may contain carriers
15 such as lactose and corn starch, and/or lubricating agents such as magnesium stearate. Capsules may contain diluents including lactose and dried corn starch. Aqueous suspensions may contain emulsifying and suspending agents combined with the active ingredient.
20 The oral dosage forms may further contain sweetening and/or flavoring and/or coloring agents.

The compounds may also be administered rectally in the form of suppositories. These compositions can be prepared by mixing the drug with a suitable non-
25 irritating excipient which is solid at room temperature, but liquid at rectal temperature and, therefore, will

melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

Furthermore, the compounds may be administered topically, especially when the conditions addressed for treatment involve areas or organs readily accessible by topical application, including neurological disorders of the eye, the skin or the lower intestinal tract. Suitable topical formulations can be readily prepared for each of these areas.

For topical application to the eye, or ophthalmic use, the compounds can be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as a solution in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, the compounds may be formulated into ointments, such as petrolatum, for ophthalmic use.

For topical application to the skin, the compounds can be formulated into suitable ointments containing the compounds suspended or dissolved in, for example, mixtures with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the compounds can be formulated into suitable lotions or creams containing the active compound suspended or dissolved in, for example,

a mixture of one or more of the following: mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

5 Topical application to the lower intestinal tract can be effected in a rectal suppository formulations (see above) or in suitable enema formulations.

 Dosage levels on the order of about 0.1 mg to about 10,000 mg of the active ingredient compound are useful in
10 the treatment of the above conditions, with preferred levels of about 0.1 mg to about 1,000 mg. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode
15 of administration.

 It is understood, however, that a specific dose level for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed; the age, body weight, general health, sex and
20 diet of the patient; the time of administration; the rate of excretion; drug combination; the severity of the particular disease being treated; and the form of administration.

 The compounds can be administered with other
25 neurotrophic agents such as neurotrophic growth factor (NGF), glial derived growth factor, brain derived growth

factor, ciliary neurotrophic factor and neurotrophin-3. The dosage level of other neurotrophic drugs will depend upon the factors previously stated and the neurotrophic effectiveness of the drug combination.

5

Pharmaceutical Compositions of the Invention

The present invention also relates to a pharmaceutical composition comprising:

- (i) a neurotrophically effective amount of the
10 compound of formula I, II, III or IV, and
- (ii) a pharmaceutically acceptable carrier.

The above discussion relating to the utility and administration of the compounds of the present invention also applies to the pharmaceutical compositions of the
15 present invention.

Examples

The following examples are illustrative of the present invention and are not intended to be limitations
20 thereon. Unless otherwise specified, all percentages are based on 100% by weight of the final compound.

EXAMPLE 1

Synthesis of (2S)-2-({1-oxo-5-phenyl}-pentyl-1-(3,3-dimethyl-1,2-dioxopentyl)pyrrolidine (1)

(2S)-2-({1-oxo-4-phenyl}butyl-N-benzylpyrrolidine. 1-
5 chloro-4-phenylbutane (1.78 g; 10.5 mmol) in 20 mL of THF
was added to 0.24 g (10 mmol) of magnesium turnings in 50
mL of refluxing THF. After the addition was complete,
the mixture was refluxed for an additional 5 hours, and
then added slowly to a refluxing solution of N-benzyl-L-
10 proline ethyl ester (2.30 g (10 mmol) in 100 mL of THF.
After 2 hours of further reflux, the mixture was cooled
and treated with 5 mL of 2 N HCl. The reaction mixture
was diluted with ether (100 mL) and washed with saturated
NaHCO₃, water and brine. The organic phase was dried,
15 concentrated and chromatographed, eluting with 5:1
CH₂Cl₂:EtOAc to obtain 2.05 g (64%) of the ketone as an
oil. ¹H NMR (CDCl₃; 300 MHz): 1.49-2.18 (m, 8H); 2.32-
2.46 (m, 1H); 2.56-2.65 (m, 2H); 2.97-3.06 (m, 1H); 3.17-
3.34 (m, 1H); 3.44-3.62 (m, 1H); 4.02-4.23 (m, 2H); 7.01-
20 7.44 (m, 10H).

(2S)-2-({1-oxo-4-phenyl}butylpyrrolidine. The ketone
compound (500 mg) and palladium hydroxide (20% on carbon,
50 mg) was hydrogenated at 40 psi in a Paar shaker
overnight. The catalyst was removed by filtration and
25 the solvent was removed in vacuo. The free amine was
obtained as a yellow oil (230 mg; 100%), ¹H NMR (CDCl₃;

35

300 MHz): 1.75-2.34 (m, 10H); 2.55 (m, 2H); 2.95 (dm, 1H); 3.45-3.95 (m, 1H); 4.05 (m, 1H); 7.37 (m, 5H).

(2S)-2-(1-oxo-4-phenyl)butyl-1-(1,2-dioxo-2-methoxyethyl)pyrrolidine. To a solution of (2S)-2-(1-

5 oxo-4-phenyl)butylpyrrolidine (230 mg; 1.0 mmol) in CH₂Cl₂ (20 mL) at 0°C was added dropwise methyloxalyl chloride (135 mg; 1.1 mmol). After stirring at 0°C for 3 hours, the reaction was quenched with saturated NH₄Cl and the organic phase was washed with water and brine and dried and concentrated. The crude residue was purified
10 on a silica gel column, eluting with 20:1 CH₂Cl₂:EtOAc to obtain 300 mg of the oxamate as a clear oil (98%), ¹H NMR (CDCl₃; 300 MHz): 1.68 (m, 4H); 1.91-2.38 (m, 4H); 2.64 (t, 2H); 3.66-3.80 (m, 2H); 3.77, 3.95 (s, 3H total);
15 4.16 (m, 2H); 4.90 (m, 1H); 7.16 (m, 3H); 7.27 (m, 2H).

(2S)-2-(1-oxo-5-phenyl)pentyl-1-(3,3-dimethyl-1,2-dioxopentyl)pyrrolidine (1). To a solution of the

oxamate above (250 mg; 0.79 mmol) in anhydrous ether (15 mL), cooled to -78°C, was added 1,1-dimethylpropyl-
20 magnesium chloride (0.8 mL of a 1.0 M solution in ether; 0.8 mmol). After stirring the resulting mixture at -78°C for 2 hours, the reaction was quenched by the addition of 2 mL of saturated NH₄Cl, followed by 100 mL of EtOAc. The organic phase was washed with brine, dried,
25 concentrated, and purified on a silica gel column, eluting with 50:1 CH₂Cl₂:EtOAc. Compound 1 was obtained

36

as a clear oil, 120 mg, ^1H NMR (CDCl_3 , 300 MHz): δ 0.87 (t, 3H, $J=7.5$); 1.22 (s, 3H); 1.25 (s, 3H); 1.67 (m, 4H); 1.70-2.33 (m, 6H); 2.61 (t, 2H, $J=7.1$); 3.52 (m, 2H); 4.17 (t, 2H, $J=6.2$); 4.52 (m, 1H); 7.16-7.49 (m, 5H).
5 Anal. Calcd. for $\text{C}_{23}\text{H}_{31}\text{NO}_3 \cdot \text{H}_2\text{O}$: C, 70.37; H, 8.86; N, 3.73. Found: 70.48; H, 8.35; N, 3.69.

EXAMPLE 2

Synthesis of 2-phenyl-1-ethyl 1-(3,3-dimethyl-1,2-
10 dioxopentyl)-2-piperidinecarbothioate (9)

Methyl (2S)-1-(1,2-dioxo-2-methoxyethyl)-2-
pyrrolidinecarboxylate. A solution of L-proline methyl
ester hydrochloride (3.08 g; 18.60 mmol) in dry methylene
chloride was cooled to 0°C and treated with triethylamine
15 (3.92 g; 36.74 mmol; 2.1 eq). After stirring the formed
slurry under a nitrogen atmosphere for 15 min, a solution
of methyl oxalyl chloride (3.20 g; 26.12 mmol) in
methylene chloride (45 mL) was added dropwise. The
resulting mixture was stirred at 0°C for 1.5 hour. After
20 filtering to remove solids, the organic phase was washed
with water, dried over MgSO_4 and concentrated. The crude
residue was purified on a silica gel column, eluting with
50% ethyl acetate in hexane, to obtain 3.52 g (88%) of
the product as a reddish oil. Mixture of cis-trans amide
25 rotamers; data for trans rotamer given. ^1H NMR (CDCl_3):
 δ 1.93 (dm, 2H); 2.17 (m, 2H); 3.62 (m, 2H); 3.71 (s, 3H);

3.79, 3.84 (s, 3H total); 4.86 (dd, 1H, $J=8.4, 3.3$).

Methyl (2S)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylate. A solution of methyl (2S)-1-(1,2-dioxo-2-methoxyethyl)-2-pyrrolidinecarboxylate (2.35 g; 10.90 mmol) in 30 mL of tetrahydrofuran (THF) was cooled to -78°C and treated with 14.2 mL of a 1.0 M solution of 1,1-dimethylpropylmagnesium chloride in THF. After stirring the resulting homogeneous mixture at -78°C for three hours, the mixture was poured into saturated ammonium chloride (100 mL) and extracted into ethyl acetate. The organic phase was washed with water, dried, and concentrated, and the crude material obtained upon removal of the solvent was purified on a silica gel column, eluting with 25% ethyl acetate in hexane, to obtain 2.10 g (75%) of the oxamate as a colorless oil, $^1\text{H NMR}$ (CDCl_3): δ 0.88 (t, 3H); 1.22, 1.26 (s, 3H each); 1.75 (dm, 2H); 1.87-2.10 (m, 3H); 2.23 (m, 1H); 3.54 (m, 2H); 3.76 (s, 3H); 4.52 (dm, 1H, $J=8.4, 3.4$).

(2S)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidine-carboxylic acid. A mixture of methyl (2S)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylate (2.10 g; 8.23 mmol), 1 N LiOH (15 mL), and methanol (50 mL) was stirred at 0°C for 30 minutes and at room temperature overnight. The mixture was acidified to pH 1 with 1 N HCl, diluted with water, and extracted into 100 mL of methylene chloride. The organic extract was washed with

brine and concentrated to deliver 1.73 g (87%) of snow-white solid which did not require further purification, ¹H NMR (CDCl₃): δ 0.87 (t, 3H); 1.22, 1.25 (s, 3H each); 1.77 (dm, 2H); 2.02 (m, 2H); 2.17 (m, 1H); 2.25 (m, 1H);
5 3.53 (dd, 2H, J=10.4, 7.3); 4.55 (dd, 1H, J=8.6, 4.1).

2-phenyl-1-ethyl-1-(3,3-dimethyl-1,2-dioxopentyl)-2-piperidinecarbothioate (9). To a solution of (2S)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylic acid (241 mg; 1.0 mmol, in CH₂Cl₂, (10 mL) was added
10 dicyclohexylcarbodiimide (226 mg; 1.1 mmol). After stirring the resulting mixture for 5 minutes, the solution was cooled to 0°C and treated with a solution of phenyl mercaptan (138 mg; 1.0 mmol) and 4-dimethylaminopyridine (6 mg) in 5 mL of CH₂Cl₂. The
15 mixture was allowed to warm to room temperature with stirring overnight. The solids were removed by filtration and the filtrate was concentrated in vacuo; the crude residue was purified by flash chromatography (10:1 hexane:EtOAc) to obtain 302 mg (84%) of **9** as an
20 oil, ¹H NMR (CDCl₃, 300 MHz): δ 0.85 (t, 3H, J=7.5); 1.29 (s, 3H); 1.31 (s, 3H); 1.70-2.32 (m, 6H); 2.92 (t, 2H, J=7.4); 3.22 (t, 2H, J=7.4); 3.58 (m, 2H); 4.72 (m, 1H); 7.23-7.34 (m, 5H). Anal. Calcd. for C₂₀H₂₇NO₃S - 0.4H₂O: C, 65.15; H, 7.60; N, 3.80. Found: C, 65.41;
25 H, 7.49; N, 3.72.

EXAMPLE 3

Synthesis of 2-phenyl-1-ethyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate (10)

Methyl 1-(1,2-dioxo-2-methoxyethyl)-2-piperidine-carboxylate. A solution of methyl pipercolate hydrochloride (8.50 g; 47.31 mmol) in dry methylene chloride (100 mL) was cooled to 0°C and treated with triethylamine (10.5 g; 103 mmol; 2.1 eq). After stirring the formed slurry under a nitrogen atmosphere for 15 minutes, a solution of methyl oxalyl chloride (8.50 g; 69.4 mmol) in methylene chloride (75 mL) was added dropwise. The resulting mixture was stirred at 0°C for 1.5 hours. After filtering to remove solids, the organic phase was washed with water, dried over MgSO₄ and concentrated. The crude residue was purified on a silica gel column, eluting with 50% ethyl acetate in hexane, to obtain 9.34 g (36%) of the product as a reddish oil. Mixture of cis-trans amide rotamers; data for trans rotamer given. ¹H NMR (CDCl₃): δ 1.22-1.45 (m, 2H); 1.67-1.78 (m, 3H); 2.29 (m, 1H); 3.33 (m, 1H); 3.55 (m, 1H); 3.76 (s, 3H); 3.85, 3.97 (s, 3H total); 4.52 (dd, 1H).

Methyl 1-(1,2-dioxo-3,3-dimethylpentyl)-2-piperidine-carboxylate. A solution of methyl 1-(1,2-dioxo-2-methoxyethyl)-2-piperidinecarboxylate (3.80 g; 16.57 mmol) in 75 mL of tetrahydrofuran (THF) was cooled to -

78°C and treated with 20.7 mL of a 1.0 M solution of 1,1-dimethyl-propylmagnesium chloride in THF. After stirring the resulting homogeneous mixture at -78°C for three hours, the mixture was poured into saturated ammonium chloride (100 mL) and extracted into ethyl acetate. The organic phase was washed with water, dried, and concentrated, and the crude material obtained upon removal of the solvent was purified on a silica gel column, eluting with 25% ethyl acetate in hexane, to obtain 3.32 g (74%) of the oxamate as a colorless oil, ¹H NMR (CDCl₃): δ 0.88 (t, 3H); 1.21, 1.25 (s, 3H each); 1.35-1.80 (m, 7H); 2.35 (m, 1H); 3.24 (m, 1H); 3.41 (m, 1H); 3.76 (s, 3H); 5.32 (d, 1H).

1-(1,3-dioxo-3,3-dimethylpentyl)-2-piperidine-carboxylic acid. A mixture of methyl 1-(1,3-dioxo-3,3-dimethylpentyl)-2-piperidinecarboxylate (3.30 g; 12.25 mmol), 1 N LiOH (15 mL), and methanol (60 mL) was stirred at 0°C for 30 minutes and at room temperature overnight. The mixture was acidified to pH 1 with 1 N HCl, diluted with water, and extracted into 100 mL of methylene chloride. The organic extract was washed with brine and concentrated to deliver 2.80 g (87%) of snow-white solid which did not require further purification, ¹H NMR (CDCl₃): δ 0.89 (t, 3H); 1.21, 1.24 (s, 3H each); 1.42-1.85 (m, 7H); 2.35 (m, 1H); 3.22 (d, 1H); 3.42 (m, 1H); 5.31 (d, 1H).

2-phenyl-1-ethyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate (10). To a solution of 1-(1,2-dioxo-3,3-dimethylpentyl)-2-piperidine-carboxylic acid (255 mg; 1.0 mmol) in CH_2Cl_2 (10 mL) was added dicyclohexylcarbodiimide (226 mg; 1.1 mmol). After stirring the resulting mixture for 5 minutes, the solution was cooled to 0°C and treated with a solution of phenyl mercaptan (138 mg; 1.0 mmol) and 4-dimethylaminopyridine (6 mg) in 5 mL of CH_2Cl_2 . The mixture was allowed to warm to room temperature with stirring overnight. The solids were removed by filtration and the filtrate was concentrated in vacuo; the crude residue was purified by flash chromatography (10:1 hexane:EtOAc) to obtain 300 mg (80%) of 10 as an oil. ^1H NMR (CDCl_3 , 300 MHz): δ 0.94 (t, 3H, $J=7.5$); 1.27 (s, 3H); 1.30 (s, 3H); 1.34-1.88 (m, 7H); 2.45 (m, 1H); 2.90 (t, 2H, $J=7.7$); 3.26 (t, 2H, $J=7.7$); 3.27 (m, 1H); 3.38 (m, 1H); 5.34 (m, 1H); 7.24-7.36 (m, 5H). Anal. Calcd. for $\text{C}_{21}\text{H}_{29}\text{NO}_3\text{S}$: C, 67.17; H, 7.78; N, 3.73. Found: C, 67.02; H, 7.83; N, 3.78.

As discussed above, the compounds of the present invention have an affinity for the FK506 binding protein, particularly FKBP12. The inhibition of the prolyl peptidyl cis-trans isomerase activity of FKBP may be measured as an indicator of this affinity.

K_i Test Procedure

Inhibition of the peptidyl-prolyl isomerase (rotamase) activity of the inventive compounds can be evaluated by known methods described in the literature (Harding et al., Nature, 1989, 341:758-760; Holt et al. J. Am. Chem. Soc., 115:9923-9938). These values are obtained as apparent K_i's and are presented for representative compounds in Table IV. The cis-trans isomerization of an alanine-proline bond in a model substrate, N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide, is monitored spectrophotometrically in a chymotrypsin-coupled assay, which releases para-nitroanilide from the trans form of the substrate. The inhibition of this reaction caused by the addition of different concentrations of inhibitor is determined, and the data is analyzed as a change in first-order rate constant as a function of inhibitor concentration to yield the apparent K_i values.

In a plastic cuvette are added 950 μ L of ice cold assay buffer (25 mM HEPES, pH 7.8, 100 mM NaCl), 10 μ L of FKBP (2.5 μ M in 10 mM Tris-Cl pH 7.5, 100 mM NaCl, 1 mM dithiothreitol), 25 μ L of chymotrypsin (50 mg/ml in 1 mM HCl) and 10 μ L of test compound at various concentrations in dimethyl sulfoxide. The reaction is initiated by the addition of 5 μ L of substrate (succinyl-Ala-Phe-Pro-Phe-para-nitroanilide, 5 mg/mL in 2.35 mM LiCl in

nerve growth factor, immunophilin ligands or combinations of NFG plus drugs. Forty-eight hours after drug treatment, the ganglia were visualized under phase contrast or Hoffman Modulation contrast with a Zeiss Axiovert inverted microscope. Photomicrographs of the explants were made, and neurite outgrowth was quantitated. Neurites longer than the DRG diameter were counted as positive, with total number of neurites quantitated per each experimental condition. Three to four DRGs are cultured per well, and each treatment was performed in duplicate.

Dose-response curves were generated from which ED_{50} values were obtained. The results of these experiments are presented in Table IV under the column "ED₅₀". Representative photomicrographs of untreated (control) sensory neurons and of compounds 1 (10 pM, 1 nM, 1 μ M), 9 (10 pM, 1 nM, 100 nM) and 10 (10 pM, 1 nM, 100 nM) promoting neurite outgrowth in sensory neurons are shown in FIG.'s 1(A-D), 2(A-D) and 3(A-D), respectively.

MPTP Model of Parkinson's Disease

The remarkable neurotrophic and neuroregenerative effects of the present inventive compounds were further demonstrated in an animal model of neurodegenerative disease. MPTP lesioning of dopaminergic neurons in mice was used as an animal model of Parkinson's Disease. Four

trifluoroethanol).

The absorbance at 390 nm versus time is monitored for 90 seconds using a spectrophotometer and the rate constants are determined from the absorbance versus time data files.

The data for these experiments for representative compounds are presented in Table IV under the column "K_i".

The neurotrophic effects of the compounds of the present invention can be demonstrated in cellular biological experiments in vitro, as described below.

Chick Dorsal Root Ganglion

Cultures and Neurite Outgrowth

The neurotrophic effects of the FKBP inhibitor compounds were demonstrated by evaluating the ability of the compounds to promote neurite outgrowth in cultured chick sensory neurons from dorsal root ganglia. Dorsal root ganglia were dissected from chick embryos of ten day gestation. Whole ganglion explants were cultured on thin layer Matrigel-coated 12 well plates with Liebovitz L15 plus high glucose media supplemented with 2 mM glutamine and 10% fetal calf serum, and also containing 10 μ M cytosine β -D arabinofuranoside (Ara C) at 37°C in an environment containing 5% CO₂. Twenty-four hours later, the DRGs were treated with various concentrations of

46

TABLE IVIn Vitro Test Results

	<u>Example #</u>	<u>Ki. nM</u>	<u>ED50. nM</u>	<u>% TH recovery</u>
	1	31	0.4	23
5	2	210	--	--
	3	85	--	--
	9	104	0.5	61
	10	12	0.8	54
	11	299	0.36	53
10	12	442	0.025	--
	14	313	0.9	48
	28	108	0.9	41
	29	59	0.003	50
	30	11	0.00025	65
15	31	8.7	--	31
	32	362	--	52
	33	1698	--	--
	34	34	0.9	48
	35	62	--	--
20	36	7	--	56
	37	68	--	--
	38	8.9	0.011	37.32

45

week old male CD1 white mice were dosed i.p. with 30 mg/kg of MPTP for 5 days. Test compounds (4 mg/kg), or vehicle, were administered s.c. along with the MPTP for 5 days, as well as for an additional 5 days following cessation of MPTP treatment. At 18 days following MPTP treatment, the animals were sacrificed and the striata were dissected and homogenized. Immunostaining was performed on sagittal and coronal brain sections using anti-tyrosine hydroxylase 1 g to quantitate survival and recovery of dopaminergic neurons. In animals treated with MPTP and vehicle, a substantial loss of functional dopaminergic terminals was observed as compared to non-lesioned animals. Lesioned animals receiving test compounds showed a significant recovery of TH-stained dopaminergic neurons.

The results of these experiments are presented in TABLE IV under the column "% TH recovery". Quantitation for the recovery of TH-positive dopaminergic neurons in the striatum of animals receiving compounds 1, 9 and 10, and for representative control and lesioned animals not receiving the test drugs, are presented in FIG. 4.

47

	39	347	--	--
	40	1226		
	41	366	--	--
	42	28	--	--
5	43	259	--	--
	44	188	--	25
	45	31	--	--
	46	757	--	--
	47	21	--	50
10	48	127	--	28
	49	1334	--	--
	50	55	--	62
	51	33	--	--
	52	6	--	--
15	53	261	--	--
	54	37	--	--
	55	30	--	--
	56	880	--	--
	57	57	--	--
20	58	79	--	--
	59	962	--	--
	60	90	--	--

48


	61	139	--	--
	62	196	--	--
	63	82	--	--
	64	163	--	--
5	65	68	--	--
	66	306	5	38
	67	177	--	--
	68	284	--	--
	69	49	--	23
10	70	457	--	25
	71	788	--	--

15 All publications and patents identified above are hereby incorporated by reference.

20 The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the following claims.

WE CLAIM:

1. A compound of formula II:



or a pharmaceutically acceptable salt thereof, wherein:

n is 1 or 2;

X is O or S;

15 Z is selected from the group consisting of S, CH₂, CHR, and C(R)₂;

20 R₁ is selected from the group consisting of C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, Ar, and mixtures thereof, wherein said R₁ is unsubstituted or substituted with halo, nitro, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, hydroxy, C₁-C₄ alkoxy, C₂-C₄ alkenyloxy, phenoxy, benzyloxy, amino, Ar, or a mixture thereof;

25 R₂ is selected from the group consisting of C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₃-C₆ cycloalkyl, C₅-C₆

cycloalkenyl and Ar₁; and

Ar₁ is phenyl, benzyl, pyridyl, fluorenyl, thioindolyl or naphthyl wherein said Ar₁ is unsubstituted or substituted with halo, hydroxy, nitro, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₁-C₄ alkoxy, C₂-C₄ alkenyloxy, phenoxy, benzyloxy, amino or a mixture thereof.

2. The compound of claim 1, wherein:

10 n is 1; and

X is O.

3. The compound of claim 2, wherein Z is CH₂.

15 4. The compound of claim 3, which is selected from the group consisting of:

(2S)-2-((1-Oxo-5-phenyl)-pentyl-1-(3,3-dimethyl-1,2-dioxopentyl)pyrrolidine;

20 3,3-Dimethyl-1-[(2S)-2-(5-(3-pyridyl)pentanoyl)-1-pyrrolidine]-1,2-pentanedione;

(2S)-2-((1-Oxo-4-phenyl)-butyl-1-(3,3-dimethyl-1,2-dioxobutyl)pyrrolidine;

(2S)-2-((1-Oxo-4-phenyl)-butyl-1-(2-cyclohexyl-1,2-dioxoethyl)pyrrolidine;

25 2-((1-Oxo-4-phenyl)-butyl-1-(3,3-dimethyl-1,2-dioxobutyl)pyrrolidine; and

51

1-((2S)-2-(5,5-di(4-Fluorophenyl)pentanoyl)-2-pyrrolidine)-3,3-dimethyl-1,2-pentanedione.

5. The compound of claim 2, wherein Z is S.

5

6. The compound of claim 5, which is selected from the group consisting of:

2-Phenyl-1-ethyl 1-(3,3-dimethyl-1,2-dioxopentyl)-2-piperidinecarbothioate;

10 (3-Thiaindolyl)methyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

2-Phenyl-1-ethyl (2S)-1-(2-cyclohexyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

15 2-Phenyl-1-ethyl (2S)-1-(1-cyclopentyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

3-Phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

3-(3-Pyridyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

20 3-Phenyl-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-pyrrolidinecarbothioate;

4-Phenyl-1-butyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-pyrrolidinecarbothioate;

25 4-Phenyl-1-butyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

3-(3-Pyridyl)-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

3,3-Diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

5 3,3-Diphenyl-1-propyl (2S)-1-(2-Cyclohexyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

3-(para-Methoxyphenyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

10 3,3-Di(para-Fluoro)phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

4,4-Di(para-fluorophenyl)butyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

3-(1-Naphthyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

15 2,2-Diphenylethyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)tetrahydro-1H-2-pyrrolecarbothioate;

3-[4-(Trifluoromethyl)phenyl]propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

20 3-(2-Naphthyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

3-(3-Chlorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

3-[3-(Trifluoromethyl)phenyl]propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

25 3-(1-Biphenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

53

3-(2-Fluorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

3-(3-Fluorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

5 3-(2-Chlorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate; and

3-(3,4-Dimethoxyphenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate.

10 7. The compound of claim 1, wherein:
n is 1; and
X is S.

8. The compound of claim 7, wherein Z is CH₂.

15

9. The compound of 7, wherein Z is S.

10. The compound of claim 1, wherein:

n is 2; and

20

X is O.

11. The compound of claim 10, wherein Z is CH₂.

12. The compound of claim 11, which is selected from
25 the group consisting of:

2-({1-Oxo-6-phenyl}-hexyl-1-(3,3-dimethyl-1,2-dioxobutyl)piperidine; and

3,3-Dimethyl-1-[2-(4-phenylpentanoyl)piperidino]-1,2-pentanedione.

5

13. The compound of claim 10, wherein Z is S.

14. The compound of claim 13, which is selected from the group consisting of:

10 3-Phenyl-1-ethyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

 2-Phenyl-1-ethyl 1-(2-phenyl-1,2-dioxoethyl)-2-piperidinecarbothioate;

15 3-Phenyl-1-propyl 1-(3,3-dimethyl-1,2-dioxobutyl)-2-piperidinecarbothioate;

 4-Phenyl-1-butyl 1-(1,2-dioxo-3,3-dimethylbutyl)-2-piperidinecarbothioate;

 1,5-Diphenyl-3-pentyl 1-(3,3-dimethyl-1,2-dioxopentyl)-2-piperidinecarbothioate;

20 1,5-Diphenyl-3-mercaptopentyl 1-(3-phenyl-1,2-dioxoethyl)-2-piperidinecarbothioate;

 3-(para-Methoxyphenyl)-1-propyl 1-(1,2-dioxo-3,3-dimethylpentyl)piperidine-2-carbothioate;

25 3-(para-Methoxyphenyl)-1-propyl 1-(2-phenyl-1,2-dioxoethyl)piperidine-2-carbothioate;

3-(1-Naphthyl)-1-propyl 1-(3,3-dimethyl-1,2-dioxopentyl)piperidine-2-carbothioate;

2,2-Diphenylethyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

5 3,3-Diphenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

3-(2-Naphthyl)propyl (2R,S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

10 4-Phenylbutyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

3-Phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

3-(2-Chlorophenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

15 3-(2-Fluorophenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate; and

3-(3-Fluorophenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate.

20 15. The compound of claim 1, wherein:

n is 2; and

X is S.

16. The compound of claim 15, wherein Z is CH₂.

25

17. The compound of 15, wherein Z is S.

18. The compound of claim 15, wherein Z is CHR_1 .

19. The compound of claim 18, which is 2-({1-Oxo-[2-(2'-phenyl)ethyl]-4-phenyl}-butyl-1-(3,3-dimethyl-1,2-dioxobutyl)piperidine.

20. A pharmaceutical composition comprising:

(i) an effective amount of the compound of claim 1 for effecting a neuronal activity; and

(ii) a pharmaceutically acceptable carrier.

21. The pharmaceutical composition of claim 20, wherein, in said compound:

n is 1; and

X is O.

22. The pharmaceutical composition of claim 21, wherein, in said compound, Z is CH_2 .

23. The pharmaceutical composition of claim 22, wherein said compound is selected from the group consisting of:

(2S)-2-({1-Oxo-5-phenyl}-pentyl-1-(3,3-dimethyl-1,2-dioxopentyl)pyrrolidine;

3,3-Dimethyl-1-[(2S)-2-(5-(3-pyridyl)pentanoyl)-1-pyrrolidine]-1,2-pentanedione;

(2S)-2-((1-Oxo-4-phenyl)-butyl-1-(3,3-dimethyl-1,2-dioxobutyl)pyrrolidine;

(2S)-2-((1-Oxo-4-phenyl)-butyl-1-(2-cyclohexyl-1,2-dioxoethyl)pyrrolidine;

5 2-((1-Oxo-4-phenyl)-butyl-1-(3,3-dimethyl-1,2-dioxobutyl)pyrrolidine; and

1-((2S)-2-[5,5-di(4-Fluorophenyl)pentanoyl]-2-pyrrolidine)-3,3-dimethyl-1,2-pentanedione.

10 24. The pharmaceutical composition of claim 21, wherein, in said compound, Z is S.

25 25. The pharmaceutical composition of claim 24, wherein said compound is selected from the group consisting of:

2-Phenyl-1-ethyl 1-(3,3-dimethyl-1,2-dioxopentyl)-2-piperidinecarbothioate;

(3-Thioindolyl)methyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

20 2-Phenyl-1-ethyl (2S)-1-(2-cyclohexyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

2-Phenyl-1-ethyl (2S)-1-(1-cyclopentyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

25 3-Phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

- 3-(3-Pyridyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;
- 3-Phenyl-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-pyrrolidinecarbothioate;
- 5 4-Phenyl-1-butyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-pyrrolidinecarbothioate;
- 4-Phenyl-1-butyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;
- 3-(3-Pyridyl)-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;
- 10 3,3-Diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;
- 3,3-Diphenyl-1-propyl (2S)-1-(3-Cyclohexyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;
- 15 3-(para-Methoxyphenyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;
- 3,3-Di(para-Fluoro)phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;
- 4,4-Di(para-fluorophenyl)butyl 1-(3,3-dimethyl-2-oxopentanyl)-2-pyrrolidinecarbothioate;
- 20 3-(1-Naphthyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanyl)-2-pyrrolidinecarbothioate;
- 2,2-Diphenylethyl (2S)-1-(3,3-dimethyl-2-oxopentanyl)tetrahydro-1H-2-pyrrolecarbothioate;
- 25 3-[4-(Trifluoromethyl)phenyl]propyl (2S)-1-(3,3-dimethyl-2-oxopentanyl)-2-pyrrolidinecarbothioate;

3-(2-Naphthyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

3-(3-Chlorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

5 3-(3-(Trifluoromethyl)phenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

3-(1-Biphenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

10 3-(2-Fluorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

3-(3-Fluorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

3-(2-Chlorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate; and

15 3-(3,4-Dimethoxyphenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate.

26. The pharmaceutical composition of claim 20, wherein, in said compound:

20 n is 1; and

X is S.

27. The pharmaceutical composition of claim 26, wherein, in said compound, Z is CH₂.

28. The pharmaceutical composition of 26, wherein,
in said compound, Z is S.

29. The pharmaceutical composition of claim 20,
5 wherein, in said compound:

n is 2; and

X is O.

30. The pharmaceutical composition of claim 29,
10 wherein, in said compound, Z is CH₂.

31. The pharmaceutical composition of claim 30,
wherein said compound is selected from the group
consisting of:

15 2-[1-(3-oxo-6-phenyl)-hexyl-1-(3,3-dimethyl-1,2-
dioxobutyl)piperidine]; and

3,3-Dimethyl-1-[2-(4-phenylpentanoyl)piperidino]-1,2-
pentanedione.

20 32. The pharmaceutical composition of claim 29,
wherein, in said compound, Z is S.

33. The pharmaceutical composition of claim 32,
wherein said compound is selected from the group
25 consisting of:

2-Phenyl-1-ethyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

2-Phenyl-1-ethyl 1-(2-phenyl-1,2-dioxoethyl)-2-piperidinecarbothioate;

5 3-Phenyl-1-propyl 1-(3,3-dimethyl-1,2-dioxobutyl)-2-piperidinecarbothioate;

4-Phenyl-1-butyl 1-(1,2-dioxo-3,3-dimethylbutyl)-2-piperidinecarbothioate;

10 1,5-Diphenyl-3-pentyl 1-(3,3-dimethyl-1,2-dioxopentyl)-2-piperidinecarbothioate;

1,5-Diphenyl-3-mercaptopentyl 1-(3-phenyl-1,2-dioxoethyl)-3-piperidinecarbothioate;

3-(para-Methoxyphenyl)-1-propyl 1-(1,2-dioxo-3,3-dimethylpentyl)piperidine-2-carbothioate;

15 3-(para-Methoxyphenyl)-1-propyl 1-(2-phenyl-1,2-dioxoethyl)piperidine-3-carbothioate;

3-(1-Naphthyl)-1-propyl 1-(3,3-dimethyl-1,2-dioxopentyl)piperidine-2-carbothioate;

20 2,2-Diphenylethyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

3,3-Diphenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

3-(2-Naphthyl)propyl (2R,S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

25 4-Phenylbutyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

3-Phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

3-(2-Chlorophenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

5 3-(2-Fluorophenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate; and

3-(3-Fluorophenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate.

10 34. The pharmaceutical composition of claim 20, wherein, in said compound:

n is 2; and

X is S.

15 35. The pharmaceutical composition of claim 34, wherein, in said compound, Z is CH₃.

36. The pharmaceutical composition of 34, wherein, in said compound, Z is S.

20

37. The pharmaceutical composition of claim 34, wherein, in said compound, Z is CHR₁.

25 38. The pharmaceutical composition of claim 37, wherein said compound is 2-({1-Oxo-[2-{2'-phenyl}ethyl]-4-phenyl}-butyl-1-(3,3-dimethyl-1,2-

dioxobutyl)piperidine.

39. A method for effecting a neuronal activity in an animal, comprising:

5 administering to the animal an effective amount of the compound of claim 1.

40. The method of claim 39, wherein the neuronal activity is selected from the group consisting of
10 stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration and treatment of neurological disorder.

41. The method of claim 40, wherein the neurological
15 disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, traumatic injury to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorder relating to
20 neurodegeneration.

42. The method of claim 41, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's Disease, Parkinson's
25 Disease, and amyotrophic lateral sclerosis.

64

43. The method of claim 39, wherein, in said compound:

n is 1; and

X is O.

5

44. The method of claim 43, wherein, in said compound, Z is CH₂.

45. The method of claim 44, wherein said compound is selected from the group consisting of:

10 (2S)-2-({1-Oxo-5-phenyl}-pentyl-1-(3,3-dimethyl-1,2-dioxopentyl pyrrolidine);

3,3-Dimethyl-1-({(2S)-2-(5-(3-pyridyl)pentanoyl)-1-pyrrolidine)-1,3-pentanedione;

15 (2S)-2-({1-Oxo-4-phenyl}-butyl-1-(3,3-dimethyl-1,2-dioxobutyl pyrrolidine);

(2S)-2-({1-Oxo-4-phenyl}-butyl-1-(2-cyclohexyl-1,2-dioxoethyl)pyrrolidine);

20 2-({1-Oxo-4-phenyl}-butyl-1-(3,3-dimethyl-1,2-dioxobutyl)pyrrolidine; and

1-({(2S)-2-[5,5-di(4-Fluorophenyl)pentanoyl]-2-pyrrolidine)-3,3-dimethyl-1,2-pentanedione.

46. The method of claim 43, wherein, in said compound, Z is S.

25

47. The method of claim 46, wherein said compound is selected from the group consisting of:

2-Phenyl-1-ethyl 1-(3,3-dimethyl-1,2-dioxopentyl)-2-piperidinecarbothioate;

5 (3-Thiaindolyl)methyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

2-Phenyl-1-ethyl (2S)-1-(2-cyclohexyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

10 2-Phenyl-1-ethyl (2S)-1-(1-cyclopentyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

3-Phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

3-(3-Pyridyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

15 3-Phenyl-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-pyrrolidinecarbothioate;

4-Phenyl-1-butyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-pyrrolidinecarbothioate;

20 4-Phenyl-1-butyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

3-(3-Pyridyl)-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

3,3-Diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

25 3,3-Diphenyl-1-propyl (2S)-1-(2-Cyclohexyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

3-(para-Methoxyphenyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

3,3-Di(para-Fluoro)phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;

5 4,4-Di(para-fluorophenyl)butyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

3-(1-Naphthyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

10 2,2-Diphenylethyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)tetrahydro-1H-2-pyrrolecicarbothioate;

3-(4-(Trifluoromethyl)phenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

3-(2-Naphthyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

15 3-(3-Chlorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

3-(3-(Trifluoromethyl)phenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

20 3-(1-Biphenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

3-(2-Fluorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

3-(3-Fluorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate;

25 3-(2-Chlorophenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate; and

3-(3,4-Dimethoxyphenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarbothioate.

48. The method of claim 39, wherein, in said
5 compound:

n is 1; and

X is S.

49. The method of claim 48, wherein, in said
10 compound, Z is CH₂.

50. The method of claim 48, wherein, in said
compound, Z is S.

51. The method of claim 39, wherein, in said
15 compound:

n is 2; and

X is O.

52. The method of claim 51, wherein, in said
20 compound, Z is CH₂.

53. The method of claim 52, wherein said compound is
selected from the group consisting of:

25 2-({1-Oxo-6-phenyl}-hexyl-1-(3,3-dimethyl-1,2-
dioxobutyl)piperidine; and

3,3-Dimethyl-1-[2-(4-phenylpentanoyl)piperidino]-1,2-pentanedione.

54. The method of claim 51, wherein, in said
5 compound, Z is S.

55. The method of claim 54, wherein said compound is selected from the group consisting of:

2-Phenyl-1-ethyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarbothioate;
10

2-Phenyl-1-ethyl 1-(2-phenyl-1,2-dioxoethyl)-2-piperidinecarbothioate;

3-Phenyl-1-propyl 1-(3,3-dimethyl-1,2-dioxobutyl)-2-piperidinecarbothioate;

15 4-Phenyl-1-butyl 1-(1,2-dioxo-3,3-dimethylbutyl)-2-piperidinecarbothioate;

1,5-Diphenyl-3-pentyl 1-(3,3-dimethyl-1,2-dioxopentyl)-2-piperidinecarbothioate;

1,5-Diphenyl-3-mercaptopentyl 1-(3-phenyl-1,2-dioxoethyl)-2-piperidinecarbothioate;
20

3-(para-Methoxyphenyl)-1-propyl 1-(1,2-dioxo-3,3-dimethylpentyl)piperidine-2-carbothioate;

3-(para-Methoxyphenyl)-1-propyl 1-(2-phenyl-1,2-dioxoethyl)piperidine-2-carbothioate;

25 3-(1-Naphthyl)-1-propyl 1-(3,3-dimethyl-1,2-dioxopentyl)piperidine-2-carbothioate;

69

2,2-Diphenylethyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

3,3-Diphenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

5 3-(2-Naphthyl)propyl (2R,S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

4-Phenylbutyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

10 3-Phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

3-(2-Chlorophenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate;

3-(2-Fluorophenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate; and

15 3-(3-Fluorophenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarbothioate.

56. The method of claim 39, wherein, in said compound:

20 n is 2; and

X is S.

57. The method of claim 56, wherein, in said compound, Z is CH₃.

25

70

58. The method of 56, wherein, in said compound, Z is S.

59. The method of claim 56, wherein in said
5 compound, Z is CHR₁.

60. The method of claim 59, wherein said compound is
2-({1-Oxo-[3-{2'-phenyl}ethyl]-4-phenyl}-butyl-1-(3,3-
dimethyl-1,2-dioxobutyl)piperidine.

Untreated



FIG. 1(A)

100 nM



FIG. 1(B)

1 nM



FIG. 1(C)

1 μM



FIG. 1(D)

2

Untreated

FIG. 2(A)

FIG. 2(B)

FIG. 2(C)

FIG. 2(D)

126

100 nM

Untreated 10 μ M



FIG. 3(A)



FIG. 3(B)



FIG. 3(C)




FIG. 3(D)

1 nM

100 nM

FIG.4

GPI Neuroimmunophilin Ligands Protect Striatal Tyrosine Hydroxylase Levels from MPTP-Toxicity In Mice



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/15832

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) .C07D 207/06, 211/14; A61K 31/40, 31/445

US CL :548/533, 546/192; 514/330, 423

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. 548/533; 546/192; 514/330, 423

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X,P	US 5,654,332 A (ARMISTEAD) 05 August 1997, claims 1-6.	1-4, 10-12, 20-23, 29-31, 39-45, 51-53
Y	US 5,252,579 A (SCOTNICKI et al.) 12 October 1993, claim 1.	1, 10, 13, 14, 29-33
Y	EP 0 048 159 A2 (UNIVERSITY OF MIAMI) 24 March 1982, claim 1.	2, 5, 6, 20, 21, 24
Y	HOLT, D.A. et al. Structure-activity studies of synthetic FKBP ligands as peptidyl-prolyl isomerase inhibitors. Bioorganic & Medicinal Chemistry Letters, 1994, volume 4, no. 2, pages 315-320, especially compound 28 in table 3 on page 318.	10-12, 30-31

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents	
A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E earlier document published on or after the international filing date	*X* document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	*A* document member of the same patent family

Date of the actual completion of the international search

15 OCTOBER 1997

Date of mailing of the international search report

10 NOV 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CHANA AULAKH

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No
PCT/US97/15832

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US97/15832

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. The species are as follows:

I. Compounds of formula II where n is 1, classifiable in class 548, subclass 533

II. Compounds of formula II where n is 2, classifiable in class 546, subclass 192.

The claims are deemed to correspond to the species listed above in the following manner:

Species I : Claims 2-9, 21-28 and 43-50.

Species II : Claims 10-19, 29-38 and 51-60.

The following claims are generic: Claims 1, 20 and 39-42.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

There is no common core Which in the Markush Practice, is a significant structural element shared by all the alternatives; see PCT Administrative Instructions Annex B Part I (f) (i) (B) (1).

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)